Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval - BioSpace

BioSpaceView source article

Part of story

Novo submits sickle cell drug for regulatory approval

Novo Nordisk has submitted a sickle cell disease drug for regulatory approval, a medicine acquired in a billion-dollar deal that the company views as a future blockbuster.

Nov 13, 2026·2 sourcesClinical trialsFast track designationHematologyDrug Policy, Pricing & ApprovalFDA drug approvalOrphan drug designationNovo NordiskPharmaceutical IndustryRare diseases
Novo submits sickle cell drug for regulatory approval
00

Other sources for this story

BioPharma Dive

Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties